Clinical Roundup

A study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. 

In children with rhabdomyosarcoma, a rare cancer that affects the muscles and other soft tissues, the presence of mutations in several genes, including TP53, MYOD1, and CDKN2A, appears to be associated with a more aggressive form of the disease and a poorer chance of survival. 

A study has demonstrated that the inherited risk of early-onset cancer is significantly higher among Latino and African American families for solid tumors, and Asian/Pacific Islander families for blood-based cancers, compared to non-Latino white families in California.

Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni. 

A study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells. 

A study by researchers at Yale Cancer Center shows that combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers. 

A study led by Yale Cancer Center researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.